Gastrointestinal Cancer,Liver Cancer HRQoL Impact of Tislelizumab vs. Sorafenib in First-line uHCC: RATIONALE-301 Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer LEAP-002 Study: Lenvatinib+Pembrolizumab vs Lenvatinib+Placebo in aHCC HRQoL Comparison Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Phase 3 Trial: Pembrolizumab vs. Placebo for Second-Line HCC Treatment in Asian Patients Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Cost-effectiveness of HCC treatments: Sintilimab + Bevacizumab vs. Lenvatinib Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Cabozantinib and Durvalumab Combo Shows Promise for GI Malignancies: CAMILLA Trial Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Analyzing the Exposure-Response of Tremelimumab and Durvalumab in Patients with Unresectable HCC Feb 16, 2023
